UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 506

Sortiert nach

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

Bioorganic & medicinal chemistry letters, 2022-10, Vol.74, p.128929-128929, Article 128929

2022

Link zum Volltext

Verfügbarkeit prüfen

A Convenient Method for the Efficient Removal of Ruthenium Byproducts Generated during Olefin Metathesis Reactions

Organic letters, 2001-05, Vol.3 (9), p.1411-1413

2001

Link zum Volltext

Verfügbarkeit prüfen

Formal Total Synthesis of (+)-Salicylihalamides A and B: A Combined Chiral Pool and RCM Strategy

Journal of organic chemistry, 2003-12, Vol.68 (26), p.10030-10039

2003

Link zum Volltext

Verfügbarkeit prüfen

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Molecular cancer therapeutics, 2021-11, Vol.20 (11), p.2098-2109

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

Bioorganic & medicinal chemistry letters, 2022-10, Vol.74, p.128928-128928, Article 128928

2022

Link zum Volltext

Verfügbarkeit prüfen

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region

Bioorganic & medicinal chemistry letters, 2010-10, Vol.20 (19), p.5793-5798

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Journal of medicinal chemistry, 2015-05, Vol.58 (10), p.4165-4179

2015

Link zum Volltext

Verfügbarkeit prüfen

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Molecular cancer therapeutics, 2015-09, Vol.14 (9), p.2023-2034

2015

Link zum Volltext

Verfügbarkeit prüfen

Short and efficient chiral pool and RCM approach towards the synthesis of the macrocyclic core of the salicylihalamides

Chemical communications (Cambridge, England), 2001-01 (3), p.255-256

2001

Link zum Volltext

Verfügbarkeit prüfen

Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.B129-B129

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4033-4033

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1639: DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agents

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1639-1639

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1640: DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agents

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1640-1640

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4938: DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4938-4938

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1613: Dimerization-induced activation of the integrated stress response kinase PERK by an investigational small molecule modulator, DP-9024

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1613-1613

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4045-4045

2023

Link zum Volltext

Verfügbarkeit prüfen

Diastereoselectivity in the transglycosidation of methyl 2-deoxy-3,4,6-tri-O-methyl-2(N-methylacetamido)-d-glucopyranoside, -galactopyranoside, and -mannopyranoside with racemic 2-butanol under reductive-cleavage conditions

Carbohydrate research, 1997-03, Vol.298 (4), p.279-289

1997

Link zum Volltext

Verfügbarkeit prüfen

Synthetic Studies with 13-Deoxybaccatin III

Journal of organic chemistry, 2002-10, Vol.67 (20), p.7140-7143

2002

Link zum Volltext

Verfügbarkeit prüfen

Mechanism of anomerization of cyclohexyl 2-deoxy-3,4,6-tri- O-methyl-2-( N-methylacetamido)- α- and β- d-hexopyranosides under reductive-cleavage conditions

Carbohydrate research, 1996-12, Vol.296 (1), p.215-227

1996

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues

Bioorganic & medicinal chemistry, 2007-01, Vol.15 (2), p.702-713

2007

Link zum Volltext

Verfügbarkeit prüfen

A convenient method to remove ruthenium byproducts from olefin metathesis reactions using polymer-bound triphenylphosphine oxide (TPPO)

Molecular diversity, 2005-11, Vol.9 (4), p.301-303

2005

Link zum Volltext

Verfügbarkeit prüfen

Diastereoselectivity in the transglycosidation of methyl [formula omitted], -galactopyranoside, and -mannopyranoside with racemic 2-butanol under reductive-cleavage conditions

Carbohydrate research, 1997, Vol.298 (4), p.279-289

1997

Link zum Volltext

Verfügbarkeit prüfen

[2+2+2] Cycloaddition reaction of 1-methylpyrrole with diethyl azodicarboxylate

Journal of organic chemistry, 1990-06, Vol.55 (12), p.3957-3958

1990

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 506

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(440)
Mit Volltextzugriff
(475)

Publikationsform

Sprache

Englisch
(427)
Koreanisch
(80)
Japanisch
(56)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(314)
Life Sciences & Biomedicine
(257)
Humans
(156)
Male
(99)
Female
(94)
Animals
(67)
Middle Aged
(63)
Adult
(55)
Aged
(51)
Physical Sciences
(47)
Original
(43)
Medicine
(38)
Retrospective Studies
(37)
Chemistry
(36)
Science & Technology - Other Topics
(35)
Oncology
(34)
Patients
(34)
Biochemistry & Molecular Biology
(33)
Mice
(33)
Risk Factors
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

A Convenient Method for the Efficient Removal of Ruthenium Byproducts Generated during Olefin Metathesis Reactions

Formal Total Synthesis of (+)-Salicylihalamides A and B: A Combined Chiral Pool and RCM Strategy

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Short and efficient chiral pool and RCM approach towards the synthesis of the macrocyclic core of the salicylihalamides

Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers

Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models

Abstract 1639: DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agents

Abstract 1640: DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agents

Abstract 4938: DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors

Abstract 1613: Dimerization-induced activation of the integrated stress response kinase PERK by an investigational small molecule modulator, DP-9024

Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models

Diastereoselectivity in the transglycosidation of methyl 2-deoxy-3,4,6-tri-O-methyl-2(N-methylacetamido)-d-glucopyranoside, -galactopyranoside, and -mannopyranoside with racemic 2-butanol under reductive-cleavage conditions

Synthetic Studies with 13-Deoxybaccatin III

Mechanism of anomerization of cyclohexyl 2-deoxy-3,4,6-tri- O-methyl-2-( N-methylacetamido)- α- and β- d-hexopyranosides under reductive-cleavage conditions

Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues

A convenient method to remove ruthenium byproducts from olefin metathesis reactions using polymer-bound triphenylphosphine oxide (TPPO)

Diastereoselectivity in the transglycosidation of methyl [formula omitted], -galactopyranoside, and -mannopyranoside with racemic 2-butanol under reductive-cleavage conditions

[2+2+2] Cycloaddition reaction of 1-methylpyrrole with diethyl azodicarboxylate

Suchergebnisse filtern